C4 Therapeutics, Inc. Increase (Decrease) in Accounts Receivable
C4 Therapeutics, Inc. (CCCC) reported Increase (Decrease) in Accounts Receivable of -$1.07 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2026-08-11
- C4 Therapeutics, Inc. increase (decrease) in accounts receivable for the quarter ending 2026-06-30 was -$1.55M.
- C4 Therapeutics, Inc. increase (decrease) in accounts receivable for the quarter ending 2026-03-31 was $482.00K, a 90.22% decline year-over-year.
- C4 Therapeutics, Inc. increase (decrease) in accounts receivable for the quarter ending 2025-12-31 was -$4.14M.
- C4 Therapeutics, Inc. increase (decrease) in accounts receivable for the quarter ending 2025-09-30 was $4.34M, a 52.68% decline year-over-year.
- C4 Therapeutics, Inc. increase (decrease) in accounts receivable for fiscal 2025 was -$701.00K.
- C4 Therapeutics, Inc. increase (decrease) in accounts receivable for fiscal 2024 was -$8.70M, a 184.22% decline from fiscal 2023.
- C4 Therapeutics, Inc. increase (decrease) in accounts receivable for fiscal 2023 was $10.33M.
- C4 Therapeutics, Inc. increase (decrease) in accounts receivable for fiscal 2022 was -$4.24M, a 444.48% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 9 month | Increase (Decrease) in Accounts Receivable 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$1.55M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$1.07M 10-Q · filed 2026-08-11 | -$5.21M derived: sum of 3 quarters · filed 2026-08-11 | -$867.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $482.00K 10-Q · filed 2026-05-12 | -$3.66M derived: sum of 2 quarters · filed 2026-05-12 | $682.00K derived: sum of 3 quarters · filed 2026-05-12 | -$5.14M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | -$4.14M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $200.00K derived: sum of 2 quarters · filed 2026-02-26 | -$5.63M derived: sum of 3 quarters · filed 2026-08-11 | -$701.00K 10-K · filed 2026-02-26 |
| 2025-09-30 | $4.34M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$1.49M derived: sum of 2 quarters · filed 2026-08-11 | $3.44M 10-Q · filed 2025-11-06 | -$3.80M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | -$5.83M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$901.00K 10-Q · filed 2026-08-11 | -$8.14M derived: sum of 3 quarters · filed 2026-08-11 | $1.03M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $4.93M 10-Q · filed 2026-05-12 | -$2.31M derived: sum of 2 quarters · filed 2026-05-12 | $6.86M derived: sum of 3 quarters · filed 2026-05-12 | -$5.57M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | -$7.24M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $1.94M derived: sum of 2 quarters · filed 2026-02-26 | -$10.50M derived: sum of 3 quarters · filed 2026-02-26 | -$8.70M 10-K · filed 2026-02-26 |
| 2024-09-30 | $9.17M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$3.26M derived: sum of 2 quarters · filed 2025-11-06 | -$1.46M 10-Q · filed 2025-11-06 | $9.84M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | -$12.43M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$10.63M 10-Q · filed 2025-08-07 | $668.00K derived: sum of 3 quarters · filed 2025-08-07 | $140.00K derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $1.80M 10-Q · filed 2025-05-07 | $13.10M derived: sum of 2 quarters · filed 2025-05-07 | $12.57M derived: sum of 3 quarters · filed 2025-05-07 | $13.07M derived: sum of 4 quarters · filed 2025-05-07 |
| 2023-12-31 | $11.30M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $10.77M derived: sum of 2 quarters · filed 2025-02-27 | $11.27M derived: sum of 3 quarters · filed 2025-02-27 | $10.33M 10-K · filed 2025-02-27 |
| 2023-09-30 | -$528.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | -$28.00K derived: sum of 2 quarters · filed 2024-10-31 | -$973.00K 10-Q · filed 2024-10-31 | -$988.00K derived: sum of 4 quarters · filed 2024-10-31 |
| 2023-06-30 | $500.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | -$445.00K 10-Q · filed 2024-08-01 | -$460.00K derived: sum of 3 quarters · filed 2024-08-01 | -$682.00K derived: sum of 4 quarters · filed 2024-08-01 |
| 2023-03-31 | -$945.00K 10-Q · filed 2024-05-08 | -$960.00K derived: sum of 2 quarters · filed 2024-05-08 | -$1.18M derived: sum of 3 quarters · filed 2024-05-08 | -$1.25M derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | -$15.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | -$237.00K derived: sum of 2 quarters · filed 2024-02-22 | -$300.00K derived: sum of 3 quarters · filed 2024-02-22 | -$4.24M 10-K · filed 2024-02-22 |
| 2022-09-30 | -$222.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-01 | -$285.00K derived: sum of 2 quarters · filed 2023-11-01 | -$4.23M 10-Q · filed 2023-11-01 | -$3.36M derived: sum of 4 quarters · filed 2023-11-01 |
| 2022-06-30 | -$63.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$4.01M 10-Q · filed 2023-08-08 | -$3.14M derived: sum of 3 quarters · filed 2023-08-08 | -$4.50M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | -$3.94M 10-Q · filed 2023-05-04 | -$3.07M derived: sum of 2 quarters · filed 2023-05-04 | -$4.44M derived: sum of 3 quarters · filed 2023-05-04 | -$1.88M derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | $871.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | -$497.00K derived: sum of 2 quarters · filed 2023-02-23 | $2.06M derived: sum of 3 quarters · filed 2023-02-23 | $1.23M 10-K · filed 2023-02-23 |
| 2021-09-30 | -$1.37M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $1.19M derived: sum of 2 quarters · filed 2022-11-03 | $361.00K 10-Q · filed 2022-11-03 | $704.00K derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | $2.56M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $1.73M 10-Q · filed 2022-08-04 | $2.07M derived: sum of 3 quarters · filed 2022-08-04 | -$2.33M derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | -$828.00K 10-Q · filed 2022-05-05 | -$485.00K derived: sum of 2 quarters · filed 2022-05-05 | -$4.89M derived: sum of 3 quarters · filed 2022-05-05 | $336.00K derived: sum of 4 quarters · filed 2022-05-05 |
| 2020-12-31 | $343.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | -$4.06M derived: sum of 2 quarters · filed 2022-02-24 | $1.16M derived: sum of 3 quarters · filed 2022-02-24 | -$139.00K 10-K · filed 2022-02-24 |
| 2020-09-30 | -$4.41M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $821.00K derived: sum of 2 quarters · filed 2021-11-10 | -$482.00K 10-Q · filed 2021-11-10 | $1.55M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-06-30 | $5.23M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11 | $3.92M 10-Q · filed 2021-08-11 | $5.95M derived: sum of 3 quarters · filed 2022-02-24 | |
| 2020-03-31 | -$1.30M 10-Q · filed 2021-05-13 | $728.00K derived: sum of 2 quarters · filed 2022-02-24 | ||
| 2019-12-31 | $2.03M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | -$81.81M 10-K · filed 2022-02-24 | ||
| 2019-09-30 | -$83.85M 10-Q · filed 2020-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |